Role of Neoadjuvant Chemotherapy followed by Concurrent Chemo-radiation in Locally Advanced Cervical Carcinoma: Our Experience

  • Shantanu Pendse Junior Resident Department of Radiation Therapy and Oncology, Government Medical College and Hospital, Nagpur-03
  • Ashok Kumar Diwan Associate Professor and Head, Department of Radiation Therapy and Oncology, Government Medical College and Hospital, Nagpur-03
Keywords: : Cervical carcinoma, Neoadjuvant chemotherapy, Cisplatin, 5-FU, Concurrent chemo radiation.


Background: Cervical carcinoma is the second most common cancer in females in India. Majority of them are reported in advanced stage. We have given platinum based neoadjuvant chemotherapy followed by CTRT in our study to reduce the local recurrence and decrease the tumor burden. The primary objective of our study was to assess the efficacy of NACT in terms of clinical and radiological response at the end of completion of treatment. Methods: This was a single arm prospective study in which we enrolled 79 patients from  2015-2017 who received 3 cycles of NACT, triweekly Cisplatin and 5-FU followed by concurrent chemo radiation (Radiotherapy-External beam radiotherapy 50Gy/25# plus intracavitary brachytherapy). Response was assessed at 12 weeks of completion of treatment by MRI pelvis using RECIST criteria 1.1 and toxicities were assessed weekly using CTCAE 4.03. Results: Mean age was 54 years; compliance rate was 88.6%. Complete response rate was 58.57% and partial response rate was 18.57% at 12 weeks post-treatment. Grade 2 or higher toxicities were seen in 52.85% patients during NACT and chemo radiation. Skin toxicities were seen in 37.14% followed by rectal-32.85%, haematological-27.14% and urinary bladder-24.28%. Conclusions: Neoadjuvant chemotherapy followed by Concurrent chemo radiation is a feasible treatment option with a good response rate with acceptable rate of treatment related toxicities.


Download data is not yet available.


1. Denny L. Cervical cancer: prevention and treatment. Discov Med. 2012;14:125–131.
2. Guidelines in Oncology.National Comprehensive Cancer Network Clinical Practice. Cervical v.1.2006.
3. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation
therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.
4. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002;20:966-72.
5. Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:1275-88.
6. World – both sexes estimated incidence by age. [Accessed October 30, 2014]. Available from:
7. Mori T, Hosokawa K, Kinoshita Y, Watanabe A, Honjo H (2008) Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma. Int J Gynecol Cancer 18: 85–89.
8. McCormack M1, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V, Simonds H, Fernando I, Hammond M, James L, Feeney A, Ledermann JA. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 2013 Jun 25;108(12):2464-9. doi: 10.1038/bjc.2013.230. Epub 2013 May 21.
9. Inoue T, Okumura M. Prognostic significance of parametrial ex- tension in patients with cervical carcinoma Stages IB, IIA, and IIB. Cancer 1984; 54:1714-1719.
10. Yoshida K1, Jastaniyah N2, Sturdza A3, Lindegaard J4, Segedin B5, Mahantshetty U6, Rai B7. Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE). Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):788-96. doi: 10.1016/j.ijrobp.2015.08.007. Epub 2015 Aug 7.
11. NCLACCM - Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 17: 2470–2486.
12. CCCMAC - Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and metaanalysis of individual patient data from 18 randomised trials. J Clin Oncol 26: 5802–5812.
13. Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516–525.
14. Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis Collaboration (NACCCMA) Collaboration. Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst Rev. 2004;(2):CD001774.
15. Rose PG, Blessing JA, Gershenson DM, McGehee R (1999) Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix Gynecologic Oncology Group study. J Clin Oncol 17: 2676–2680.
How to Cite
Pendse S, Diwan A. Role of Neoadjuvant Chemotherapy followed by Concurrent Chemo-radiation in Locally Advanced Cervical Carcinoma: Our Experience. IABCR [Internet]. 20Mar.2018 [cited 20Mar.2019];4(1):4-. Available from: